1 / 13

Saxenda ( L iraglutide )

Saxenda ( L iraglutide ). Samuel Gyawu-Amoateng. Indication & Approval. Saxenda , is FDA approved as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity Drug was approved in December 23 rd 2014

manning
Download Presentation

Saxenda ( L iraglutide )

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Saxenda (Liraglutide) Samuel Gyawu-Amoateng

  2. Indication & Approval • Saxenda, is FDA approved as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity • Drug was approved in December 23rd 2014 • It is approved in adults with BMI of 30 or greater (obesity) or adults with BMI of 27 or greater (overweight) with at least one weight-related condition such as HTN, T2DM, or Dyslipidemia.

  3. Drug Class • Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist also known as incretinmimitic. Therefore is should not be used with other drugs belonging to the same class such as Victoza, for T2DM.

  4. MOA • A long acting analog of human glucagon-like peptide- (GLP-1) (an incretin hormone) which • increases glucose-dependent insulin secretion, • decreases inappropriate glucagon secretion, • increase's B-cell growth/replication, • slows gastric emptying, and decreases food intake. • It’s administration results in decreases in hemoglobin A1c by ~1%

  5. Dosage & Formulation • Initial 0.6mg SubQ once daily for 1 week, increase by 0.6mg daily at weekly intervals to target the dose of 3mg once daily. • If 3mg dose is not tolerated, d/c therapy since efficacy has not been established at lower doses. • Evaluate changes in body weight 16 weeks after starting of therapy. d/c if at least 4% of baseline body weight loss has not been achieved. • No dosage adjustments for renal or mild-to-severe hepatic impairment patient.

  6. Administration & Storage • Drug is administered SuBQ in the upper arm, thigh or abdomen. • Should not be injected IV, or IM. • Can be administered w/o food at any time of the day • Store at 36 to 46 degree F, prior to initial use, and same temp after initial use • Do not freeze, discard if freezing occurs • Discard pen 30 days after initial use

  7. PK , PD • It is highly protein bound. Approximately 98% • VdSubQ is ~ 13- 25 L • Endogenously metabolized by dipeptidyl peptidase IV (DPP-IV) and endogenous endopeptidases • Metabolism is slower than native GLP-1 • T1/2 ~ 13 hours • Peak plasma ~ 8-12 hours

  8. Side Effects and Adverse Effects • Nausea, vomiting, diarrhea, tiredness, decrease appetite, headache • Renal impairment • Hypoglycemia, • Gall bladder problems • BBW : Thyroid Tumors: Dose dependent and treatment duration-dependent thyroid C-cell tumors.

  9. Contraindications • Saxenda is contraindicated in patients with: • 1. Hypersensitive to liraglutide or an component of the product [2] • 2. Personal or family history of medullary thyroid carcinoma [1, 2] • 3. Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN2) [1, 2] • Pregnancy [1]

  10. Usage

  11. CO$T! CO$T!! CO$T!!! • 6 mg/mL (3 mL) : $256.39 [1]

  12. Counseling Pearls & Monitoring • Saxenda approved with a Risk Evaluation and Mitigation Strategy (REMS) program. • Pregnancy Category X: Do not use if pregnant or plan on getting pregnant soon. • If dose is missed for 3 days or more, contact doctor on how to restart • Alternate injection site • Monitor for signs & symptoms of hypoglycemia • Monitor for signs and symptoms of pancreatitis, • Monitor for mood changes or behavioral changes.

  13. Credits • [1.] Lexicomphttp://0-online.lexi.com.wildpac.wne.edu/lco/action/doc/retrieve/docid/patch_f/2144379 • [2.] Micromedex http://0-www.micromedexsolutions.com.wildpac.wne.edu/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/984F15/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/CFB70A/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=2814&contentSetId=31&title=LIRAGLUTIDE&servicesTitle=LIRAGLUTIDE# • [3.] Liraglutide med guide

More Related